Travere Therapeutics (NASDAQ: TVTX) reported first‑quarter 2026 revenue of $127.2 million, falling short of the $129.6 million consensus estimate, while its non‑GAAP adjusted earnings per share of $0.05 beat the $‑0.26 consensus estimate, giving the company a $0.31 per‑share beat.
The earnings beat was largely driven by disciplined cost management. Travere reported a lower cost of goods sold than expected, offsetting the revenue shortfall and allowing the company to post a positive adjusted EPS despite a modest revenue miss.
Revenue growth was supported by record demand for its flagship drug FILSPARI in both the IgA nephropathy and the newly approved focal segmental glomerulosclerosis indications. The company highlighted that the commercial platform for FILSPARI is expanding, with sales momentum continuing in both indications.
Management reiterated that the company remains on track to achieve profitability in the second half of 2026 and will continue to focus on expanding the FILSPARI commercial platform while advancing its pegtibatinase pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.